Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This article describes a power-efficient, high dynamic range (DR) incremental ADC (IADC) for wearable biopotential signals recording, where DC and low-frequency disturbances such as electrode offset, 50/60 Hz interference and motion artifact must be tolerated. To achieve a wide DR, the IADC performs a three-step conversion by combining zoom-SAR and extended counting (EC) on top of a second-order incremental delta-sigma modulator (ΔΣM). The hybrid architecture notably reduces the oversampling ratio (OSR) with respect to conventional incremental ΔΣMs, while using the EC further improves the Signal-to-Noise-and-Distortion Ratio (SNDR) by 7.4 to 25.6 dB. Fabricated in a 0.18-μm CMOS technology, the IADC achieves 107.6-dB DR, 104.9-dB peak SNR, and 99.3-dB peak SNDR at 2 kS/s while dissipating 130 μW from 1.8-V (analog) / 1.2-V (digital) supply. This translates to a highly competitive FoM of 176.5 dB. The high-DR IADC reduces the gain of the preceding instrumentation amplifier (IA) such that significant DC and low-frequency disturbances can be tolerated. The advantages of high DR have been demonstrated by wearable Electrocardiography (ECG) and Electroencephalography (EEG) recordings under motion artifact.

Download full-text PDF

Source
http://dx.doi.org/10.1109/TBCAS.2023.3312976DOI Listing

Publication Analysis

Top Keywords

incremental adc
8
biopotential signals
8
signals recording
8
low-frequency disturbances
8
motion artifact
8
1076 db-dr
4
db-dr three-step
4
incremental
4
three-step incremental
4
adc motion-tolerate
4

Similar Publications

Purpose: To validate the performance of three multiparametric quantitative sequences, including amide proton transfer-weighted (APTw) MRI, diffusion kurtosis imaging (DKI) and apparent diffusion coefficient (ADC), in the enhancement of biopsy decision-making in patients with Prostate Imaging-Reporting and Data System (PI-RADS) core of 3-4.

Materials And Methods: A total of 96 participants who scored as PI-RADS 3-4 according to PI-RADS v2.1 and pathologically confirmed were enrolled.

View Article and Find Full Text PDF

Objectives: Predicting longer-term response to biological therapy for small bowel Crohn's disease (SBCD) is an unmet clinical need. Diffusion-weighted magnetic resonance (MR) imaging (DWI) may indicate disease activity, but its predictive ability, if any, is unknown. We investigated the prognostic value of DWI for 1 year response or remission (RoR) in SBCD patients commencing biologic therapy, including incremental value over C-reactive protein (CRP) and faecal calprotectin (FC).

View Article and Find Full Text PDF

Background: Both the antibody-drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.

Objectives: To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.

View Article and Find Full Text PDF

Introduction: Fluid assessment and management is a key aspect of good dialysis care and is affected by patient-level characteristics and potentially centre-level practices. In this secondary analysis of the BISTRO trial we wished to establish whether centre-level practices with the potential to affect fluid status were stable over the course of the trial and explore if they had any residual associations with participant's fluid status.

Methods: Two surveys (S) of fluid management practices were conducted in 32 participating centres during the trial, (S1: 2017-18 and S2: 2021-22).

View Article and Find Full Text PDF

Purpose: To estimate the cost-effectiveness of axi-cel vs. salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem-cell transplantation (HDT+ASCT) for responders to second-line treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

Methods: A partitioned survival mixture-cure model comprising three health states was used to estimate the costs, life years gained (LYG), and quality-adjusted life years (QALYs) accumulated over a lifetime horizon.

View Article and Find Full Text PDF